Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024
10 août 2023 16h05 HE
|
Beyond Air™
GARDEN CITY, N.Y., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Reported commercial sales for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Currently have in...
Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD)
07 août 2023 16h05 HE
|
Beyond Air™
Data to be presented at the 2023 International Society of Neurochemistry (ISN) and the European Society of Neurochemistry (ESN) meeting in Portugal Data provides further evidence that selective...
Beyond Air® To Participate in BTIG’s 2023 Virtual Biotechnology Conference
01 août 2023 16h05 HE
|
Beyond Air™
GARDEN CITY, N.Y., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...
Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast
24 juil. 2023 16h05 HE
|
Beyond Air™
GARDEN CITY, N.Y., July 24, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...
Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023
22 juin 2023 16h05 HE
|
Beyond Air™
Successfully completed phase 1 of U.S. commercial launch, with multiple hospitals contracted, and have initiated phase 2 of launch for LungFit® PH for the treatment of term and near-term neonates with...
Beyond Air® Secures up to $40 Million Debt Financing
15 juin 2023 16h10 HE
|
Beyond Air™
GARDEN CITY, N.Y., June 15, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem
15 juin 2023 16h05 HE
|
Beyond Air™
Hebrew University’s preclinical results recently published in Advanced Science show a reversal of the molecular, synaptic and behavioral autism spectrum disorder (ASD) phenotypes Plan to initiate a...
Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast
16 mai 2023 16h05 HE
|
Beyond Air™
GARDEN CITY, N.Y., May 16, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting
19 avr. 2023 09h00 HE
|
Beyond Air™
Single and repeat dosing of UNO improves outcomes compared to checkpoint inhibitor monotherapy in the aggressive 4T1 breast cancer model mPD-L1 upregulation following UNO treatment helps to elucidate...
Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer
23 mars 2023 16h05 HE
|
Beyond Air™
GARDEN CITY, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...